Vault-13

Deep Track Capital, LP

GREENWICH, CT · CIK 1856083 · 13F filing filed 2024-08-14

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$3.3bn reported value -3.7% vs Q1 2024
67positions
41.7%in top 10
11 new 22 added 19 reduced 9 sold out vs Q1 2024

Options: 1 call positions ($1.8m notional), 0 put positions (— notional) – listed below, not included above.

Holdings, Q2 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 AMGEN INC COM AMGN AMGN 575,000 $179.7m5.37% 5.37% AddedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 550.0k, Q2 2024 575.0k +25.0k +25,000 4.5%
2 ARGENX SE SPONSORED ADR ARGX ARGX 400,000 $172.0m5.14% 5.14% AddedShares held: Q3 2023 0, Q4 2023 300.0k, Q1 2024 300.0k, Q2 2024 400.0k +100.0k +100,000 33.3%
3 AXSOME THERAPEUTICS INC COM AXSM AXSM 1,852,784 $149.1m4.45% 4.45% AddedShares held: Q3 2023 1.1m, Q4 2023 1.0m, Q1 2024 1.3m, Q2 2024 1.9m +548.1k +548,063 42.0%
4 DYNE THERAPEUTICS INC COM DYN DYN 4,000,000 $141.2m4.22% 4.22% ReducedShares held: Q3 2023 2.4m, Q4 2023 2.0m, Q1 2024 4.6m, Q2 2024 4.0m -555.4k -555,383 -12.2%
5 SPRINGWORKS THERAPEUTICS INC COM SWTX SWTX 3,700,000 $139.4m4.16% 4.16% AddedShares held: Q3 2023 3.5m, Q4 2023 4.1m, Q1 2024 3.5m, Q2 2024 3.7m +220.1k +220,147 6.3%
6 INSMED INC COM PAR $.01 INSM INSM 2,000,000 $134.0m4.00% 4.00% ReducedShares held: Q3 2023 6.0m, Q4 2023 5.3m, Q1 2024 4.8m, Q2 2024 2.0m -2.8m -2,783,679 -58.2%
7 GUARDANT HEALTH INC COM GH GH 4,500,000 $130.0m3.88% 3.88% ReducedShares held: Q3 2023 4.0m, Q4 2023 5.0m, Q1 2024 6.0m, Q2 2024 4.5m -1.5m -1,500,000 -25.0%
8 DYNAVAX TECHNOLOGIES CORP COM NEW DVAX DVAX 10,900,000 $122.4m3.66% 3.66% AddedShares held: Q3 2023 6.8m, Q4 2023 7.1m, Q1 2024 9.1m, Q2 2024 10.9m +1.8m +1,758,340 19.2%
9 ALNYLAM PHARMACEUTICALS INC COM ALNY ALNY 500,000 $121.5m3.63% 3.63% ReducedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 832.3k, Q2 2024 500.0k -332.3k -332,310 -39.9%
10 INTELLIA THERAPEUTICS INC COM NTLA NTLA 4,800,000 $107.4m3.21% 3.21% AddedShares held: Q3 2023 2.0m, Q4 2023 2.2m, Q1 2024 4.2m, Q2 2024 4.8m +589.2k +589,216 14.0%
11 INTRA-CELLULAR THERAPIES INC COM ITCI ITCI 1,537,922 $105.3m3.15% 3.15% AddedShares held: Q3 2023 2.6m, Q4 2023 2.0m, Q1 2024 1.5m, Q2 2024 1.5m +37.9k +37,922 2.5%
12 APELLIS PHARMACEUTICALS INC COM APLS APLS 2,500,000 $95.9m2.86% 2.86% AddedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 1.0m, Q2 2024 2.5m +1.5m +1,500,000 150.0%
13 IONIS PHARMACEUTICALS INC COM IONS IONS 2,000,000 $95.3m2.85% 2.85% AddedShares held: Q3 2023 2.8m, Q4 2023 1.2m, Q1 2024 1.4m, Q2 2024 2.0m +626.5k +626,525 45.6%
14 OCULAR THERAPEUTIX INC COM OCUL OCUL 12,721,460 $87.0m2.60% 2.60% UnchangedShares held: Q3 2023 0, Q4 2023 9.2m, Q1 2024 12.7m, Q2 2024 12.7m
15 4D MOLECULAR THERAPEUTICS IN COM FDMT FDMT 4,061,401 $85.2m2.55% 2.55% AddedShares held: Q3 2023 2.8m, Q4 2023 2.3m, Q1 2024 3.0m, Q2 2024 4.1m +1.0m +1,026,948 33.8%
16 ALKERMES PLC SHS ALKS ALKS 3,500,000 $84.3m2.52% 2.52% UnchangedShares held: Q3 2023 3.8m, Q4 2023 4.0m, Q1 2024 3.5m, Q2 2024 3.5m
17 NURIX THERAPEUTICS INC COM NRIX NRIX 3,991,500 $83.3m2.49% 2.49% AddedShares held: Q3 2023 3.0m, Q4 2023 3.0m, Q1 2024 3.0m, Q2 2024 4.0m +993.7k +993,670 33.1%
18 IMMUNOVANT INC COM IMVT IMVT 2,883,736 $76.1m2.27% 2.27% AddedShares held: Q3 2023 2.8m, Q4 2023 1.0m, Q1 2024 493.4k, Q2 2024 2.9m +2.4m +2,390,384 484.5%
19 BICYCLE THERAPEUTICS PLC SPONSORED ADS BCYC BCYC 3,490,506 $70.6m2.11% 2.11% UnchangedShares held: Q3 2023 3.5m, Q4 2023 3.5m, Q1 2024 3.5m, Q2 2024 3.5m
20 PLIANT THERAPEUTICS INC COM PLRX PLRX 5,972,257 $64.2m1.92% 1.92% AddedShares held: Q3 2023 5.5m, Q4 2023 5.8m, Q1 2024 5.8m, Q2 2024 6.0m +222.3k +222,257 3.9%
21 TRAVERE THERAPEUTICS INC COM TVTX TVTX 7,370,000 $60.6m1.81% 1.81% UnchangedShares held: Q3 2023 7.4m, Q4 2023 7.4m, Q1 2024 7.4m, Q2 2024 7.4m
22 VERONA PHARMA PLC SPONSORED ADS VRNA VRNA 4,000,000 $57.8m1.73% 1.73% AddedShares held: Q3 2023 3.2m, Q4 2023 3.2m, Q1 2024 3.2m, Q2 2024 4.0m +812.6k +812,585 25.5%
23 ABIVAX SA SPONSORED ADS ABVX ABVX 4,179,763 $55.3m1.65% 1.65% ReducedShares held: Q3 2023 0, Q4 2023 4.3m, Q1 2024 4.3m, Q2 2024 4.2m -117.7k -117,675 -2.7%
24 GERON CORP COM GERN GERN 13,000,000 $55.1m1.65% 1.65% ReducedShares held: Q3 2023 25.7m, Q4 2023 29.6m, Q1 2024 30.5m, Q2 2024 13.0m -17.5m -17,505,929 -57.4%
25 AUTOLUS THERAPEUTICS PLC SPON ADS AUTL AUTL 15,272,172 $53.1m1.59% 1.59% UnchangedShares held: Q3 2023 15.0m, Q4 2023 11.9m, Q1 2024 15.3m, Q2 2024 15.3m
26 TG THERAPEUTICS INC COM TGTX TGTX 2,870,131 $51.1m1.52% 1.52% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 2.9m
27 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 3,923,849 $51.0m1.52% 1.52% AddedShares held: Q3 2023 3.0m, Q4 2023 3.6m, Q1 2024 3.5m, Q2 2024 3.9m +467.8k +467,796 13.5%
28 KYMERA THERAPEUTICS INC COM KYMR KYMR 1,500,000 $44.8m1.34% 1.34% AddedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 1.3m, Q2 2024 1.5m +237.8k +237,754 18.8%
29 MIND MEDICINE MINDMED INC COM NEW COM NEW 6,103,817 $44.0m1.31% 1.31% ReducedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 6.7m, Q2 2024 6.1m -562.9k -562,850 -8.4%
30 OLEMA PHARMACEUTICALS INC COM OLMA OLMA 4,000,000 $43.3m1.29% 1.29% AddedShares held: Q3 2023 1.9m, Q4 2023 1.9m, Q1 2024 3.2m, Q2 2024 4.0m +774.6k +774,581 24.0%
31 TERNS PHARMACEUTICALS INC COM COM 6,100,000 $41.5m1.24% 1.24% UnchangedShares held: Q3 2023 6.0m, Q4 2023 6.1m, Q1 2024 6.1m, Q2 2024 6.1m
32 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 1,756,667 $41.3m1.23% 1.23% AddedShares held: Q3 2023 0, Q4 2023 2.0m, Q1 2024 1.2m, Q2 2024 1.8m +543.2k +543,247 44.8%
33 APOGEE THERAPEUTICS INC COM COM 1,000,000 $39.4m1.18% 1.18% ReducedShares held: Q3 2023 2.4m, Q4 2023 2.3m, Q1 2024 2.3m, Q2 2024 1.0m -1.3m -1,323,456 -57.0%
34 STRUCTURE THERAPEUTICS INC SPONSORED ADS GPCR GPCR 950,000 $37.3m1.11% 1.11% AddedShares held: Q3 2023 1.9m, Q4 2023 300.0k, Q1 2024 40.1k, Q2 2024 950.0k +909.9k +909,863 2266.9%
35 ANI PHARMACEUTICALS INC COM ANIP ANIP 466,089 $29.7m0.89% 0.89% ReducedShares held: Q3 2023 400.0k, Q4 2023 600.0k, Q1 2024 822.0k, Q2 2024 466.1k -355.9k -355,912 -43.3%
36 EDITAS MEDICINE INC COM EDIT EDIT 6,000,000 $28.0m0.84% 0.84% AddedShares held: Q3 2023 7.1m, Q4 2023 5.5m, Q1 2024 5.5m, Q2 2024 6.0m +472.7k +472,710 8.6%
37 CLIMB BIO INC COM CLYM CLYM 3,904,785 $27.8m0.83% 0.83% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 3.9m
38 HILLEVAX INC COM COM 1,832,652 $26.5m0.79% 0.79% ReducedShares held: Q3 2023 2.9m, Q4 2023 2.9m, Q1 2024 2.6m, Q2 2024 1.8m -739.8k -739,808 -28.8%
39 KORRO BIO INC COM KRRO KRRO 770,645 $26.1m0.78% 0.78% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 770.6k
40 SILENCE THERAPEUTICS PLC ADS SLN SLN 1,359,745 $25.8m0.77% 0.77% ReducedShares held: Q3 2023 2.0m, Q4 2023 2.0m, Q1 2024 1.6m, Q2 2024 1.4m -284.1k -284,136 -17.3%
41 NEKTAR THERAPEUTICS COM COM 17,875,498 $22.2m0.66% 0.66% ReducedShares held: Q3 2023 18.4m, Q4 2023 18.4m, Q1 2024 18.4m, Q2 2024 17.9m -524.5k -524,502 -2.9%
42 ENGENE HOLDINGS INC COM COM 2,250,000 $21.2m0.63% 0.63% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 2.2m, Q2 2024 2.2m
43 ALECTOR INC COM ALEC ALEC 4,631,998 $21.0m0.63% 0.63% AddedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 3.8m, Q2 2024 4.6m +862.6k +862,612 22.9%
44 89BIO INC COM ETNB ETNB 2,294,011 $18.4m0.55% 0.55% NewShares held: Q3 2023 91.1k, Q4 2023 0, Q1 2024 0, Q2 2024 2.3m
45 FATE THERAPEUTICS INC COM FATE FATE 5,572,607 $18.3m0.55% 0.55% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 5.6m, Q2 2024 5.6m
46 INOVIO PHARMACEUTICALS INC COM SHS INO INO 2,066,720 $16.7m0.50% 0.50% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 2.1m
47 PRAXIS PRECISION MEDICINES I COM NEW PRAX PRAX 389,546 $16.1m0.48% 0.48% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 389.5k
48 CYBIN INC COM COM 58,139,535 $15.8m0.47% 0.47% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 58.1m, Q2 2024 58.1m
49 CONTEXT THERAPEUTICS INC COM CNTX CNTX 7,419,355 $14.9m0.44% 0.44% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 7.4m
50 PYXIS ONCOLOGY INC COMMON STOCK PYXS PYXS 4,184,100 $13.8m0.41% 0.41% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 4.2m, Q2 2024 4.2m
51 INVIVYD INC COM IVVD IVVD 10,953,937 $12.0m0.36% 0.36% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 11.0m, Q2 2024 11.0m
52 ZURA BIO LTD CLASS A ORD SHS ZURA ZURA 3,283,783 $11.5m0.34% 0.34% AddedShares held: Q3 2023 2.5m, Q4 2023 2.5m, Q1 2024 2.5m, Q2 2024 3.3m +760.8k +760,783 30.1%
53 KURA ONCOLOGY INC COM KURA KURA 384,756 $7.9m0.24% 0.24% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 384.8k
54 CYTOKINETICS INC COM NEW CYTK CYTK 132,495 $7.2m0.21% 0.21% NewShares held: Q3 2023 0, Q4 2023 288.9k, Q1 2024 0, Q2 2024 132.5k
55 REGULUS THERAPEUTICS INC COM RGLS RGLS 3,262,564 $5.8m0.17% 0.17% ReducedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 3.3m, Q2 2024 3.3m -4.0k -4,002 -0.1%
56 ALTO NEUROSCIENCE INC COM SHS ANRO ANRO 511,686 $5.5m0.16% 0.16% ReducedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 600.0k, Q2 2024 511.7k -88.3k -88,314 -14.7%
57 AGENUS INC COM NEW AGEN AGEN 313,359 $5.2m0.16% 0.16% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 313.4k
58 ALLAKOS INC COM ALLKG ALLKG 5,000,000 $5.0m0.15% 0.15% UnchangedShares held: Q3 2023 0, Q4 2023 2.5m, Q1 2024 5.0m, Q2 2024 5.0m
59 SYROS PHARMACEUTICALS INC COM NEW SYRS SYRS 828,485 $4.3m0.13% 0.13% UnchangedShares held: Q3 2023 828.5k, Q4 2023 828.5k, Q1 2024 828.5k, Q2 2024 828.5k
60 RELMADA THERAPEUTICS INC COM RLMD RLMD 1,234,773 $3.7m0.11% 0.11% ReducedShares held: Q3 2023 2.8m, Q4 2023 2.0m, Q1 2024 1.2m, Q2 2024 1.2m -5.3k -5,261 -0.4%
61 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 186,386 $3.4m0.10% 0.10% NewShares held: Q3 2023 2.8m, Q4 2023 2.5m, Q1 2024 0, Q2 2024 186.4k
62 SCHOLAR ROCK HLDG CORP COM SRRK SRRK 372,559 $3.1m0.09% 0.09% ReducedShares held: Q3 2023 353.9k, Q4 2023 1.0m, Q1 2024 680.0k, Q2 2024 372.6k -307.4k -307,441 -45.2%
63 REPARE THERAPEUTICS INC COM RPTX RPTX 904,261 $3.0m0.09% 0.09% ReducedShares held: Q3 2023 3.1m, Q4 2023 3.0m, Q1 2024 2.7m, Q2 2024 904.3k -1.8m -1,780,083 -66.3%
64 COGENT BIOSCIENCES INC COM COGT COGT 308,235 $2.6m0.08% 0.08% ReducedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 316.0k, Q2 2024 308.2k -7.8k -7,765 -2.5%
65 VIGIL NEUROSCIENCE INC COM VIGL VIGL 597,215 $2.4m0.07% 0.07% ReducedShares held: Q3 2023 1.8m, Q4 2023 1.6m, Q1 2024 1.6m, Q2 2024 597.2k -997.7k -997,716 -62.6%
66 ALIGOS THERAPEUTICS INC COM COM 6,102,770 $2.1m0.06% 0.06% UnchangedShares held: Q3 2023 0, Q4 2023 6.1m, Q1 2024 6.1m, Q2 2024 6.1m
67 METAGENOMI INC COM MGX MGX 466,232 $1.9m0.06% 0.06% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 466.2k, Q2 2024 466.2k

Sold out since Q1 2024

SecurityTickerShares held beforeValue then
TOURMALINE BIO INC TRML TRML 1,595,400 $36.5m1.6m shares
PACIFIC BIOSCIENCES CALIF IN PACB PACB 7,000,000 $26.2m7.0m shares
NUVALENT INC 274,512 $20.6m274.5k shares
AGENUS INC 31,697,539 $18.4m31.7m shares
NEUMORA THERAPEUTICS INC. NMRA NMRA 1,000,000 $13.8m1.0m shares
ANAPTYSBIO INC ANAB ANAB 529,452 $11.9m529.5k shares
ULTRAGENYX PHARMACEUTICAL IN RARE RARE 167,784 $7.8m167.8k shares
MERSANA THERAPEUTICS INC 579,674 $2.6m579.7k shares
PRIME MEDICINE INC PRME PRME 303,716 $2.1m303.7k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
NEUMORA THERAPEUTICS INC. NMRA · Call NMRACall 180,500 $1.8m180.5k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on. The largest 25 of 27.

CompanyTickerStakeChange ScheduleLast filed
LB PHARMACEUTICALS INC LBRX · 13D · filed 2026-02-10 LBRX 11.7%≈ $108.8m -3.2 pts 13D 2026-02-10
ALTIMMUNE INC ALT · 13G · filed 2026-04-30 ALT 10.0%≈ $59.0m new 13G 2026-04-30
PROMIS NEUROSCIENCES INC PMN · 13G · filed 2026-02-06 PMN 10.0%≈ $11.9m new 13G 2026-02-06
VERASTEM INC VSTM · 13G · filed 2025-11-21 VSTM 10.0%≈ $29.5m new 13G 2025-11-21
COMPASS PATHWAYS PLC CMPS · 13G · filed 2025-01-17 CMPS 10.0% new 13G 2025-01-17
RAPT THERAPEUTICS INC 13G · filed 2024-12-23 9.9% new 13G 2024-12-23
MOONLAKE IMMUNOTHERAPEUTICS MLTX · 13G · filed 2026-08-14 MLTX 9.7%≈ $155.7m +3.3 pts 13G 2026-08-14
OCULAR THERAPEUTIX INC OCUL · 13G · filed 2026-05-15 OCUL 9.5%≈ $204.7m +4.4 pts 13G 2026-05-15
MAZE THERAPEUTICS INC MAZE · 13G · filed 2025-08-14 MAZE 9.0%≈ $117.8m +2.1 pts 13G 2025-08-14
IMMUNIC INC 13G · filed 2026-03-04 8.7% new 13G 2026-03-04
ALECTOR INC ALEC · 13G · filed 2026-10-23 ALEC 8.6%≈ $21.3m new 13G 2026-10-23
TARSUS PHARMACEUTICALS INC TARS · 13G · filed 2026-05-15 TARS 8.5%≈ $226.6m +1.4 pts 13G 2026-05-15
X4 PHARMACEUTICALS INC XFOR · 13G · filed 2026-08-14 XFOR 8.3%≈ $37.6m -1.7 pts 13G 2026-08-14
CONTEXT THERAPEUTICS INC CNTX · 13G · filed 2025-05-15 CNTX 8.3%≈ $4.1m 13G 2025-05-15
HEMAB THERAPEUTICS HLDGS INC COAG · 13G · filed 2026-05-08 COAG 8.2%≈ $132.3m new 13G 2026-05-08
CORMEDIX INC CRMD · 13G · filed 2026-05-15 CRMD 7.9%≈ $49.3m +1.7 pts 13G 2026-05-15
NURIX THERAPEUTICS INC NRIX · 13G · filed 2026-08-14 NRIX 7.5%≈ $187.7m +1.3 pts 13G 2026-08-14
CENTURY THERAPEUTICS INC IPSC · 13G · filed 2026-01-15 IPSC 7.3%≈ $33.0m new 13G 2026-01-15
ACLARIS THERAPEUTICS INC ACRS · 13G · filed 2026-03-17 ACRS 7.0%≈ $49.4m new 13G 2026-03-17
AVALO THERAPEUTICS INC AVTX · 13G · filed 2026-08-14 AVTX 6.9%≈ $66.7m +1.1 pts 13G 2026-08-14
MIND MEDICINE MINDMED INC 13G · filed 2025-11-14 6.9% -1.3 pts 13G 2025-11-14
ENGENE HOLDINGS INC 13G · filed 2025-11-18 6.7% +2.3 pts 13G 2025-11-18
BICARA THERAPEUTICS INC BCAX · 13G · filed 2026-05-15 BCAX 6.2%≈ $120.6m +1.2 pts 13G 2026-05-15
ALUMIS INC ALMS · 13G · filed 2026-04-07 ALMS 6.0%≈ $207.2m new 13G 2026-04-07
STRUCTURE THERAPEUTICS INC GPCR · 13G · filed 2026-02-13 GPCR 6.0% -1.4 pts 13G 2026-02-13

Trades reported as a company insider in Q2 2024

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2024-05-10 NEKTAR THERAPEUTICS 10% owner · See Footnote NKTR Sold 56,000 $99.7k56.0k shares -<1%